Current and future options in cholesterol lowering treatments.
Anti PCSK9 monoclonal antibodies
Bempedoic acid
Ezetimibe
Inclisiran
Lipid lowering agents
Statins
Journal
European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
22
10
2022
revised:
31
01
2023
accepted:
10
02
2023
medline:
29
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
The relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: statins, ezetimibe, anti PCSK9 monoclonal antibodies, the small interfering RNA (siRNA) agent, Inclisiran, and Bempedoic acid. The recent changes in lipid lowering regimens, including the early combination of lipid lowering agents and "Low LDL-C" levels <30 mg/dL for high/very high cardiovascular risk patients will also be discussed.
Identifiants
pubmed: 36813611
pii: S0953-6205(23)00050-X
doi: 10.1016/j.ejim.2023.02.010
pii:
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Cholesterol
97C5T2UQ7J
Ezetimibe
EOR26LQQ24
Anticholesteremic Agents
0
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-5Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declarations of Competing Interest The author declare he has no conflict of interest.